Corneal Neurotization as a Treatment for Neurotrophic Keratopathy
Primary Purpose
Neurotrophic Corneal Ulcer, Neurotrophic Keratitis, Cranial Nerve V Diseases
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Corneal neurotization
Sponsored by
About this trial
This is an interventional treatment trial for Neurotrophic Corneal Ulcer focused on measuring Corneal neurotization, neurotrophic cornea, neurotrophic corneal ulcer
Eligibility Criteria
Inclusion Criteria: Patients with neurotrophic cornea Exclusion Criteria: Patients with history of penetrating keratoplasty
Sites / Locations
- Andrea Kossler
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Corneal neurotization
Arm Description
Patients will undergo the corneal neurotization as described in the protocol. Their pre and post-procedure corneal sensation will be measured as a primary outcome measure. Secondary outcome measures will include visual acuity, corneal opacity, NEI VFQ, and confocal microscopy.
Outcomes
Primary Outcome Measures
Corneal sensation
Corneal sensation will be measured via Cochet Bonnet esthesiometry
Secondary Outcome Measures
Visual acuity
Measurement using Snellen eye chart
Corneal opacity
Measured based on grade 0-4 based on degree of opacity.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05809245
Brief Title
Corneal Neurotization as a Treatment for Neurotrophic Keratopathy
Official Title
Corneal Neurotization Via Sural Nerve Transfer or Cadaveric Nerve Graft for Neurotrophic Keratopathy
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Terminated
Why Stopped
Difficulties with recruitment
Study Start Date
March 15, 2018 (Actual)
Primary Completion Date
February 12, 2020 (Actual)
Study Completion Date
February 12, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Stanford University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to assess the efficacy of sural nerve transfer and cadaveric nerve graft to re-establish corneal sensation in patients with neurotrophic keratopathy.
Detailed Description
Corneal anesthesia, which can lead to visually devastating outcomes from ulceration, perforation, and scarring, can be recalcitrant to both medical and surgical treatment[1-3]. Neurotization is a revolutionary technique reported to restore corneal sensation in neurotrophic keratopathy[4-6]. Prior techniques described include direct neurotization with contralateral supraorbital and supratrochlear nerves accessed via a bicoronal incision of the scalp over the forehead[5]; nerve grafting with contralateral supratrochlear nerves accessed via a medial upper eyelid incision[6]; and sural nerve grafting to contralateral supratrochlear nerves accessed via a transverse incision over the medial upper eyelid[4]. Despite the challenges associated with these techniques (needing to subcutaneously tunnel the nerve graft over the nasal bridge or requiring a large bicoronal incision), these techniques all demonstrated efficacy in direct neurotization to improve corneal sensation in these patients.
The investigators aim to assess the efficacy of this innovative surgical technique involving coaptation of the sural nerve or cadaveric nerve allograft to an intact sensory branch of the trigeminal nerve to restore corneal sensation. The investigators have previously described the anatomic feasibility of using the infraorbital nerve using a cadaveric model, of which the results were presented at the American Society of Ophthalmic Plastic and Reconstructive Society Fall meeting in 2017. Utilization of the infraorbital nerve provides advantages over existing techniques due to ease of access via a cosmetically favorable incision, large caliber with increased ability to create a perineural window, relatively short and direct tunnel with possibly more rapid neurotization, and absence of complex surrounding anatomical structures. Others have previously describe success using the contralateral and ipsilateral supraorbital nerve and supratrochlear nerve.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neurotrophic Corneal Ulcer, Neurotrophic Keratitis, Cranial Nerve V Diseases
Keywords
Corneal neurotization, neurotrophic cornea, neurotrophic corneal ulcer
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Corneal neurotization
Arm Type
Experimental
Arm Description
Patients will undergo the corneal neurotization as described in the protocol. Their pre and post-procedure corneal sensation will be measured as a primary outcome measure. Secondary outcome measures will include visual acuity, corneal opacity, NEI VFQ, and confocal microscopy.
Intervention Type
Procedure
Intervention Name(s)
Corneal neurotization
Intervention Description
Autologous sural nerve will be harvested or cadaveric nerve graft will be coapted to an intact sensory branch of the trigeminal nerve. The nerve will be separated into fascicles which will be tunneled under the conjunctiva around the cornea near the limbus.
Primary Outcome Measure Information:
Title
Corneal sensation
Description
Corneal sensation will be measured via Cochet Bonnet esthesiometry
Time Frame
Baseline (pre-operative) to 12 months postoperatively
Secondary Outcome Measure Information:
Title
Visual acuity
Description
Measurement using Snellen eye chart
Time Frame
Baseline (pre-operative) to 12 months postoperatively
Title
Corneal opacity
Description
Measured based on grade 0-4 based on degree of opacity.
Time Frame
Baseline (pre-operative) to 12 months postoperatively
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with neurotrophic cornea
Exclusion Criteria:
Patients with history of penetrating keratoplasty
Facility Information:
Facility Name
Andrea Kossler
City
Palo Alto
State/Province
California
ZIP/Postal Code
94303
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
17212990
Citation
Ramaesh K, Stokes J, Henry E, Dutton GN, Dhillon B. Congenital corneal anesthesia. Surv Ophthalmol. 2007 Jan-Feb;52(1):50-60. doi: 10.1016/j.survophthal.2006.10.004.
Results Reference
background
PubMed Identifier
14631406
Citation
Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. Eye (Lond). 2003 Nov;17(8):989-95. doi: 10.1038/sj.eye.6700616.
Results Reference
background
PubMed Identifier
26451380
Citation
Mantelli F, Nardella C, Tiberi E, Sacchetti M, Bruscolini A, Lambiase A. Congenital Corneal Anesthesia and Neurotrophic Keratitis: Diagnosis and Management. Biomed Res Int. 2015;2015:805876. doi: 10.1155/2015/805876. Epub 2015 Sep 16.
Results Reference
background
PubMed Identifier
25010775
Citation
Elbaz U, Bains R, Zuker RM, Borschel GH, Ali A. Restoration of corneal sensation with regional nerve transfers and nerve grafts: a new approach to a difficult problem. JAMA Ophthalmol. 2014 Nov;132(11):1289-95. doi: 10.1001/jamaophthalmol.2014.2316.
Results Reference
background
PubMed Identifier
19116544
Citation
Terzis JK, Dryer MM, Bodner BI. Corneal neurotization: a novel solution to neurotrophic keratopathy. Plast Reconstr Surg. 2009 Jan;123(1):112-120. doi: 10.1097/PRS.0b013e3181904d3a.
Results Reference
background
PubMed Identifier
28570404
Citation
Sepehripour S, Lloyd MS, Nishikawa H, Richard B, Parulekar M. Surrogate Outcome Measures for Corneal Neurotization in Infants and Children. J Craniofac Surg. 2017 Jul;28(5):1167-1170. doi: 10.1097/SCS.0000000000003677.
Results Reference
background
Learn more about this trial
Corneal Neurotization as a Treatment for Neurotrophic Keratopathy
We'll reach out to this number within 24 hrs